001 BR Dec 2020

ASH 2020: Takeda demonstrates the essential role real-world evidence plays in personalised treatments

Takeda presented nine abstracts at the 62nd ASH Annual Meeting & Exposition, all utilising real-world evidence from the treatment of haemophilia, von Willebrand disease and sickle cell disease Takeda are using real-world evidence (RWE) from studies across rare bleeding disorders to demonstrate the crucial role understanding patterns of care play outside of clinical studies play in […]

Read More
001 BS Jan 2021

MHRA completed consultation on real-world evidence in December 2020

Guidance issued for Sponsors planning to conduct clinical research to support regulatory decisions Use of RWE has the potential for increasing the speed and reducing the cost of development programmes, which would see effective medications being approved more quickly The MHRA encourages Sponsors to explore the opportunities presented by the utilisation of RWE RWE just […]

Read More